Advances in the Treatment of Renal Cell Carcinoma
dc.contributor.editor | Reynolds, Paul | |
dc.contributor.editor | Stewart, Grant D | |
dc.date.accessioned | 2022-03-21T16:27:09Z | |
dc.date.available | 2022-03-21T16:27:09Z | |
dc.date.issued | 2022 | |
dc.identifier | ONIX_20220321_9783036529356_21 | |
dc.identifier.uri | https://directory.doabooks.org/handle/20.500.12854/79585 | |
dc.description.abstract | This Special Issue of Cancers focuses on new advances in the treatment of renal cell carcinoma, both surgical and pharmacological (and combinations of these), and novel approaches to tackle treatment resistance and improve our understanding of this phenomenon. | |
dc.language | English | |
dc.subject.classification | thema EDItEUR::M Medicine and Nursing | en_US |
dc.subject.other | renal cell carcinoma | |
dc.subject.other | autophagy | |
dc.subject.other | hydroxychloroquine | |
dc.subject.other | chloroquine | |
dc.subject.other | ROC-325 | |
dc.subject.other | cysteine cathepsins | |
dc.subject.other | cysteine cathepsin inhibitors | |
dc.subject.other | lysosome | |
dc.subject.other | renal cancer | |
dc.subject.other | metastatic renal cell carcinoma | |
dc.subject.other | immune-based combination therapies | |
dc.subject.other | network meta-analysis | |
dc.subject.other | PD-L1 | |
dc.subject.other | predictive | |
dc.subject.other | biomarker | |
dc.subject.other | treatment | |
dc.subject.other | TKIs | |
dc.subject.other | mRCC | |
dc.subject.other | biomarkers | |
dc.subject.other | soluble factors | |
dc.subject.other | immunotherapy | |
dc.subject.other | renal cell carcinoma (RCC) | |
dc.subject.other | sunitib resistance | |
dc.subject.other | artesunate (ART) | |
dc.subject.other | Traditional Chinese Medicine (TCM) | |
dc.subject.other | growth inhibition | |
dc.subject.other | ferroptosis | |
dc.subject.other | reactive oxygen species (ROS) | |
dc.subject.other | clear cell renal cell carcinoma | |
dc.subject.other | ccRCC | |
dc.subject.other | RCC | |
dc.subject.other | kidney cancer | |
dc.subject.other | evolution | |
dc.subject.other | evolutionary trajectory | |
dc.subject.other | metastatic | |
dc.subject.other | second line therapy | |
dc.subject.other | renal cell cancer | |
dc.subject.other | immune checkpoint inhibitors | |
dc.subject.other | tyrosine kinase inhibitors | |
dc.subject.other | individualization | |
dc.subject.other | genomic signature | |
dc.subject.other | transcriptomic analysis | |
dc.title | Advances in the Treatment of Renal Cell Carcinoma | |
dc.type | book | |
oapen.identifier.doi | 10.3390/books978-3-0365-2934-9 | |
oapen.relation.isPublishedBy | 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 | |
oapen.relation.isbn | 9783036529356 | |
oapen.relation.isbn | 9783036529349 | |
oapen.pages | 221 | |
oapen.place.publication | Basel |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |